the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

Dated: July 6, 1998.

Laura M. Tarantino,
Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 98–19893 Filed 7–24–98; 8:45 am] BILLY CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Granulocytes for Transfusion: Research and Clinical Experience; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following public workshop: Granulocytes for Transfusion: Research and Clinical Experience. This workshop, which is cosponsored by FDA and the National Institutes of Health (NIH), will include: (1) The current scientific and clinical experience with cytokine mobilized granulocyte transfusion products; (2) the effects of cytokine administration on normal donors; (3) the functional properties of transfusion product; and (4) studies needed to establish the safety and effectiveness of the transfusion product. The information obtained from these presentations will assist FDA in assessing the safety and effectiveness of the product and will assist NIH in identifying areas in need of further research.

Transcripts: Transcripts of the workshop may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, 5600 Fishers Lane, room 12A–16, Rockville, MD 20857, approximately 15 working days after the workshop at a cost of 10 cents per page.

Dated: July 17, 1998.

William B. Schultz,
Deputy Commissioner for Policy.

[FR Doc. 98–19955 Filed 7–24–98; 8:45 am] BILLY CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Evaluation of In Vivo Efficacy of Platelet Transfusion Products and Platelet Substitutes; Public Workshop

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

The Food and Drug Administration (FDA) is announcing the following public workshop: Evaluation of In Vivo Efficacy of Platelets and Platelet Substitutes. This workshop is cosponsored by FDA, the United States Army, and the National Institutes of Health. The topics to be discussed include: Current methodology for efficacy assessment of transfused platelets; definition of efficacy for platelet substitutes; animal models of platelet efficacy; discussion of the therapeutic “cost versus benefit” of using platelets treated with novel decontamination treatments or stored with novel media/methods, or of using platelet substitutes.

Date and Time: The public workshop will be held on Monday, September 28, 1998, 8 a.m. to 5 p.m.

Location: The public workshop will be held at Wilson Hall, Bldg. 1, National...